Company: CGCT
Filing Date: 2025-01-29
Form Type: S-1
Source: 0001104659-25-006780
Chunk: 94

Company: Cartesian Growth Corp III
Filing Date: 2025-01-29
Form: S-1
Chunk 94
---
 be a maximum of 23,000,000 units if
the underwriters’ over-allotment option is exercised in full, and therefore that such founder shares would represent 20% of the
outstanding ordinary shares after this offering. Our public shareholders may incur material dilution due to such anti-dilution adjustments
that result in the issuance of Class A ordinary shares on a greater than one-to-one basis upon conversion. Up to 750,000 of the founder
shares will be surrendered by our sponsor to us for no consideration depending on the extent to which the underwriters’ over-allotment
option is exercised. The founder shares will be worthless if we do not complete an initial business combination, except to the extent
they receive liquidating distributions from assets outside of the trust account. In addition, our sponsor and Cantor, the representative
of the underwriters, have committed to purchase an aggregate of 6,000,000 private placement warrants, each exercisable to purchase one
Class A ordinary share at $11.50 per share, at a price of $1.00 per private placement warrant, or $6,000,000 in the aggregate, in
a private placement that will close simultaneously with the closing of this offering. Of those 6,000,000 private placement warrants, our
sponsor has agreed to purchase 4,000,000 private placement warrants and Cantor has agreed to purchase 2,000,000 private placement warrants.
The private placement warrants will be worthless if we do not complete our initial business combination. The personal and financial interests
of our officers and directors may influence their motivation in identifying and selecting a target business combination, completing an
initial business combination and influencing the operation of the business following the initial business combination. This risk may become
more acute as the end of the completion window nears, which is the deadline for our completion of an initial business combination.

Our independent directors have a financial interest in our founder shares through DirectorCo. They acquired that interest at no cost. As a result, our independent directors have a financial interest in consummating an initial business combination, even if our shares decline in value after that business combination and our public shareholders experience losses in connection with their investment. However, if we do not consummate our initial business combination, the founder shares would be worthless. The financial interest of our independent directors in the founder shares may give rise to a potential conflict of interest in considering potential target businesses. You should consider this potential conflict of interest in deciding